Related Experiment Video
Updated: Mar 22, 2026
07:51
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
8.2K
ASSESSMENT OF ADVERSE DRUG REACTIONS AS CARDIOVASCULAR RISK FACTORS
Summary
Many medications can cause cardiovascular side effects, leading to new or worsened heart conditions. Recognizing and preventing these drug-induced cardiovascular risk factors is crucial for patient safety.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Internal Medicine
Background:
- Pharmaceutical substances can cause cardiovascular changes, exacerbating existing conditions or creating new risk factors.
- Iatrogenic conditions, or those caused by medical examination or treatment, are increasingly recognized as significant contributors to cardiovascular disease.
Purpose of the Study:
- To investigate iatrogenic conditions that manifest as cardiovascular risk factors.
- To analyze the incidence and characteristics of drug-induced cardiovascular risk factors in a patient cohort.
Main Methods:
- A descriptive study was conducted on patients admitted to the Iasi Vth Internal Medicine and Geriatrics-Gerontology Clinic.
- Data was collected retrospectively between 1998 and 2013, focusing on iatrogenic conditions linked to cardiovascular risk.
Main Results:
- Diagnosed cases included drug-induced hypertension (81), hypertensive crises (43), iatrogenic hyperglycemia (72), drug-induced hyperuricemia (36), drug-induced dyslipidemias (50), and iatrogenic obesity (17).
- These iatrogenic conditions were more prevalent in women and the elderly.
- Twenty-eight patients experienced simultaneous adverse drug reactions from the same drug, presenting as multiple cardiovascular risk factors.
Conclusions:
- Chronic drug administration can significantly induce cardiovascular risk factors.
- Certain medications, including NSAIDs, corticoids, beta-blockers, diuretics, and contraceptives, can exert multiple pathogenic effects.
- Adverse drug reactions can lead to persistent or reversible cardiovascular risk factors, emphasizing the importance of risk-benefit assessment for medication safety.
Related Concept Videos
01:19Pharmacovigilance
1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
01:24Drug Toxicity: Risk factors
147
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
147
01:23Assessment of the Cardiovascular System I: Subjective Data
1.0K
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
1.0K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.5K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.5K
01:00Drug Toxicity: Overview
163
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
163
01:29Therapeutic Drug Monitoring: Affecting Factors
322
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
322